HC Wainwright Has Optimistic Outlook of AURA FY2024 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Research analysts at HC Wainwright boosted their FY2024 earnings per share estimates for shares of Aura Biosciences in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($1.69) for the year, up from their prior estimate of ($1.71). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.45) EPS, FY2025 earnings at ($1.94) EPS and FY2026 earnings at ($2.06) EPS.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02.

A number of other equities research analysts also recently commented on AURA. Scotiabank raised their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. JMP Securities lifted their price target on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. BTIG Research boosted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Finally, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Down 2.4 %

Shares of NASDAQ:AURA opened at $8.92 on Monday. Aura Biosciences has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The firm’s 50-day simple moving average is $9.85 and its 200-day simple moving average is $8.55. The company has a market cap of $445.55 million, a price-to-earnings ratio of -5.16 and a beta of 0.33.

Insiders Place Their Bets

In other news, insider Janet Jill Hopkins sold 11,822 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the completion of the transaction, the insider now directly owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the completion of the sale, the insider now directly owns 329,847 shares in the company, valued at approximately $3,971,357.88. The trade was a 7.04 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 79,081 shares of company stock worth $891,353. 5.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Long Focus Capital Management LLC raised its position in shares of Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. grew its stake in Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after acquiring an additional 216,266 shares during the period. Wellington Management Group LLP acquired a new position in Aura Biosciences in the 3rd quarter valued at $1,037,000. Bank of New York Mellon Corp lifted its stake in shares of Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after purchasing an additional 48,549 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares during the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.